Journal for ImmunoTherapy of Cancer (Oct 2021)
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
- David Goldstein,
- Anna Spreafico,
- Ilan Weinreb,
- Trevor J. Pugh,
- Scott V Bratman,
- Bayardo Perez-Ordonez,
- Aaron R Hansen,
- Lillian Siu,
- Antony Tin,
- Alexey Aleshin,
- Amy Prawira,
- Jonathan Irish,
- John de Almeida,
- Douglas Chepeha,
- Stephen Smith,
- Marc Oliva,
- Daniel V Araujo,
- J. Javier Diaz-Mejia,
- Peter Olson,
- Tina Shek,
- Andrew Hope,
- Dax Torti,
- Jeffrey P. Bruce,
- Ben X. Wang,
- Anthony Fortuna,
- Hirak Der-Torossian,
- Ronald Shazer,
- Nickolas Attanasio,
- Qingyan Au,
- Jordan Feeney,
- Himanshu Sethi,
- Isan Chen
Affiliations
- David Goldstein
- Department of Otolaryngology and Head and Neck Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
- Anna Spreafico
- Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
- Ilan Weinreb
- Department of Pathology, University Health Network, Toronto, Ontario, Canada
- Trevor J. Pugh
- Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Scott V Bratman
- Radiation Medicine Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
- Bayardo Perez-Ordonez
- Department of Pathology, University Health Network, Toronto, Ontario, Canada
- Aaron R Hansen
- Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
- Lillian Siu
- Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
- Antony Tin
- Natera Inc, San Carlos, California, USA
- Alexey Aleshin
- Natera Inc, San Carlos, California, USA
- Amy Prawira
- Department of Medical Oncology, The Kinghorn Cancer Centre, St Vincent’s Hospital, Sidney, New South Wales, Australia
- Jonathan Irish
- Department of Otolaryngology and Head and Neck Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
- John de Almeida
- Department of Otolaryngology and Head and Neck Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
- Douglas Chepeha
- Department of Otolaryngology and Head and Neck Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
- Stephen Smith
- Department of Pathology, University Health Network, Toronto, Ontario, Canada
- Marc Oliva
- Department of Medical Oncology, Institut Catala d’ Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain
- Daniel V Araujo
- Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
- J. Javier Diaz-Mejia
- Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Peter Olson
- Department of Research, Mirati Therapeutics, San Diego, California, USA
- Tina Shek
- Radiation Medicine Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
- Andrew Hope
- Radiation Medicine Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
- Dax Torti
- Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Jeffrey P. Bruce
- Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Ben X. Wang
- Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Anthony Fortuna
- Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Hirak Der-Torossian
- Clinical Development, Mirati Therapeutics, San Diego, California, USA
- Ronald Shazer
- Clinical Development, Mirati Therapeutics, San Diego, California, USA
- Nickolas Attanasio
- Neogenomics Laboratories, Fort Myers, Florida, USA
- Qingyan Au
- Neogenomics Laboratories, Fort Myers, Florida, USA
- Jordan Feeney
- Natera Inc, San Carlos, California, USA
- Himanshu Sethi
- Natera Inc, San Carlos, California, USA
- Isan Chen
- Clinical Development, Mirati Therapeutics, San Diego, California, USA
- DOI
- https://doi.org/10.1136/jitc-2021-003476
- Journal volume & issue
-
Vol. 9,
no. 10
Abstract
No abstracts available.
